The following report features FDA Clinical Trial Updates for: QLT Inc. (NASDAQ:QLTI), Living Cell Technologies (ASX:LCT), BioMimetic Therapeutics (NASDAQ:BMTI), Array BioPharma (NASDAQ:ARRY)
QLTI: VISUDYNE (veteporfin), photodynamic or PDT light activated drug therapy, co-developed/marketed with Novartis, first approved treatment for certain forms for wet age related macular degeneration (AMD),combination studies with anti-VEGF (Lucentis) and steroid for wet AMD, expects to complete QLT sponsored RADICAL study mid-2010 for estimated results 3Q10. Updated 6/6/10.
LCT.AX: DIABACELL, encapsulated porcine islet, insulin-producing cell implants, next phase of trial with 4 new patients by July 2010 with interim results expected Oct 2010, final results at 1 year follow up, reported Phase 1/2a Russian study follow up results that met safety and proof of concept result that met safety and prro of concepts results for Type 1 diabetics, scheduled to present results at ADA meeting June 25-29,2010. Updated 6/6/10.
BMTI: Augment Bone Graft, a synthetic, off the shelf bone growth factor product, completed enrolment in EU pivotal study Nov 2008 for treatment of foot and ankle fusions with 108 patients, expects to report data mid-2010 and submit this data long with US pivotal stuffy data for regulatory approval in Europe during 3Q10. Updated 6/6/10.
ARRY: ARRY-520, a kinesin spindle protein or KSP inhibitor anti-cancer, presented on 6/5/10, Phase 1 results well tolerated with encouraging preliminary results for treatment of multiple myeloma (MM), advancing into Phase 2 portion as single-agent for MM during 3Q10, Phase ½ study for acute myeloid leukemia with estimated results during 3Q10. Updated 6/6/10.
[[T_F]]Data Leak Prevention – Data Security Solutions – Information Theft Protection, Detection and Prevention Software Productstracefusion_signature=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[[T_F]]
Initially starting in the film industry, during the past three years, Edoardo has studied the financial markets along with a few of his closest friends and began writing as an editor for one of the largest newspaper publications in his city. This offered him the opportunity to meet new co-workers and lifelong friends which ultimately led to him into moving onto helping form TheMarketFinancial.com.
His portfolio style often follow the biotech field, with a mixture of long and short ideas, and has been quoted in a number of well known online financial publications. He prides in investigative research through the use of SEC filings, FDA calendars and mainstream media in order to bring about the most interesting stories to life.
Edoardo Lopezpineda
